Physician profile
Heemesh D Seth
NPI 1548421514
$3,564.58
in general payments reported to CMS, 2019-2025
33 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $221 · 2021: $172 · 2022: $203 · 2023: $611 · 2024: $781 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.29 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $367.28 | 2019 | |
| Glaxosmithkline, LLC. | $332.64 | 2020-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $326.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $314.50 | 2019-2025 | Tagrisso, Airsupra, Imfinzi |
| Abiomed | $296.86 | 2023-2024 | Impella |
| Insmed, INC. | $296.67 | 2019-2025 | Arikayce |
| United Therapeutics Corporation | $190.81 | 2021-2025 | Tyvaso |
| Grifols USA, LLC | $173.42 | 2020-2024 | Prolastin-C Liquid |
| Penumbra, INC. | $165.69 | 2025 | Indigo System |
| Caris Mpi, INC. | $140.18 | 2025 | Mi Cancer Seek |
| Actelion Pharmaceuticals US, INC. | $136.33 | 2023-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $93.45 | 2022-2025 | Dupixent |
| Electromed, INC. | $83.27 | 2024-2025 | Smartvest |
| Ekos Corporation | $66.61 | 2019 | |
| Astellas Pharma US INC | $63.20 | 2025 | Cresemba |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $59.51 | 2019 | |
| Amgen INC. | $57.57 | 2022-2024 | Tezspire |
| Jazz Pharmaceuticals INC. | $42.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $38.69 | 2022-2025 | Zerbaxa |
| Mylan Specialty L.P. | $38.58 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.44 | 2021-2023 | Glassia |
| Advanced Respiratory, INC | $27.54 | 2020-2021 | |
| Viatris Specialty LLC | $26.55 | 2025 | Yupelri |
| Viiv Healthcare Company | $26.18 | 2025 | Dovato |
| Philips North America LLC | $22.36 | 2020 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Avadel Cns Pharmaceuticals, LLC | $16.84 | 2025 | Lumryz |
| Pfizer INC. | $16.19 | 2022 | |
| Baxter Healthcare | $14.56 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Pulmonx Corporation | $13.34 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.17 | 2020 | |
| Veran Medical Technologies, INC. | $10.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heemesh Seth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.